Company Overview and News

 
Godrej Properties Limited - Updates

2h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

 
Godrej Properties Limited - Shareholders meeting

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

 
D-Street Buzz: Over 300 stocks hit fresh 52-week low on NSE; IT gains with Infibeam up 11%, realty stocks bleed

2018-09-24 moneycontrol
It is Monday mayhem on Dalal Street which is witnessing continued bloodbath as the Indian stock market is down 1.5 percent. The Nifty50 is down over 170 points and is trading below the 11,ooo mark while the Sensex is trading lower by 500 points at 36,328.
SWANENERGY TCHQY 532834 532832 532755 535789 532480 CAMLINFIN EICHERMOT CLNDY ASHOKLEY EXIDEIND RELCAPITAL 511072 ALBK JETAIRWAYS YYBKY 517334 AKLD 531213 TECHM DHFL EXQDY TCS COALINDIA AKLS IBREALEST 533271 533150 532617 533273 ASHOKA DELTAMAGNT TTNQY 533278 505200 MOZTY 532540 532187 MANAPPURAM 500477 503100 500111 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY 532648 504286 IBULHSGFIN OBZIY GODREJPROP OBEROIRLTY MOTHERSUMI 500086 503310

 
Godrej Properties Limited - Press Release

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

 
Godrej Properties Limited - Disclosure under SEBI Takeover Regulations

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

 
Kalpataru in deal with Indian Hume Pipe to develop 15 acre Pune land

2018-09-10 livemint
Mumbai: Mumbai-based real estate firm Kalpataru Ltd has entered into a joint development agreement with pipe manufacturer Indian Hume Pipe Co. Ltd, to develop a 15-acre land parcel for a residential project in suburban Pune.
GODREJPROP INDIANHUME 533150 504741

 
Prestige Estates to enter NCR with 2 projects

2018-09-06 livemint
Bengaluru: South India-focused developer Prestige Estates Projects Ltd is set to enter the national capital region with two projects this financial year, said Venkat K. Narayana, the chief executive of the real estate firm.
MAHLIFE PRESTIGE MGEVF GODREJPROP 533150 533274 532313

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...